SignalSilence®OTULIN siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit OTULIN expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence®siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
原厂资料:
Description
SignalSilence®OTULIN siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit OTULIN expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence®siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
CST recommends transfection with 100 nM SignalSilence®OTULIN siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Background
Protein ubiquitination and deubiquitination are reversible processes catalyzed by ubiquitinating enzymes (UBEs) and deubiquitinating enzymes (DUBs) (1,2). Five subfamilies of DUBs have been characterized to date, and include USP, UCH, OTU, MJD, and JAMM deubiquitinating enzymes (1,2). The ovarian tumor (OTU) DUB subfamily comprises a group of approximately 100 putative cysteine proteases that are homologous to theDrosophilaovarian tumor gene product (3). OTU domain-containing deubiquitinase with linear linkage specificity (OTULIN, FAM105B, Gumby) is an OTU subfamily deubiquitinating enzyme that antagonizes the E3 linear ubiquitin chain assembly complex (LUBAC) by promoting disassembly of Met1-linked (linear) ubiquitin chains (4,5). LUBAC and OTULIN regulate NOD2 signaling in an antagonistic manner by controlling the level of Met1-ubiquitinated RIPK2 kinase (6). Binding of the OTULIN PUB-interacting motif to the HOIP subunit of LUBAC is critical for OTULIN inhibition of NF-κΒ signaling; this OTULIN-HOIP interaction is negatively regulated by tyrosine phosphorylation of OTULIN (7,8). The ability of OTULIN to influence LUBAC function and the presence of linear ubiquitin chains may play an important role in regulating angiogenesis, craniofacial, and neural development (5).